GSKMEX:GSKN 73 Days Payable is 435.05 as of Mar. 2026, which is 204% above its 10-year median of 143.21. GuruFocus rates MEX:GSKN with a GF Score™ of 73/100 and a GF Value™ of MXN818.82 (Fairly Valued). The stock has 1 warning sign investors should review. Among 923 Drug Manufacturers companies, GSK ranks better than 95.02% on this metric.
GSK's average Accounts Payable for the
three
months ended in Mar. 2026 was MXN214,936 Mil. GSK's Cost of Goods Sold for the
three
months ended in Mar. 2026 was MXN45,082 Mil.
Hence, GSK's Days Payable for the
three
months ended in Mar. 2026 was 435.05.
The historical rank and industry rank for GSK's Days Payable or its related term are showing as below:
MEX:GSKN'
s Days Payable Range Over the Past 10 Years
Min: 119.83 Med: 143.21 Max: 517.76
Current: 517.76
During the past 13 years, GSK's highest Days Payable was 517.76. The lowest was 119.83. And the median was 143.21.
MEX:GSKN's Days Payable is ranked better than 95.02% of 923
companies
in the Drug Manufacturers industry
Industry Median: 90.98
vs MEX:GSKN: 517.76
GSK's Days Payable
declined
from Mar. 2025 (438.17) to Mar. 2026 (435.05).
It may suggest that GSKaccelerated paying its suppliers.
GSK Days Payable Related Terms
GSK Days Payable Historical Data
* Premium members only.
The historical data trend for GSK's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:GSKN vs LLY, JNJ, ABBV: Days Payable Comparison
For the Drug Manufacturers - General subindustry, GSK's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GSK Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GSK's Days Payable distribution charts can be found below:
* The bar in red indicates where GSK's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
GSK's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GSK (MEX:GSKN) has a Days Payable of 435.05 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on GSK and its competitors. This is 204% above median its historical median of 143.21. Over the past decade, GSK's Days Payable has ranged from 119.83 to 517.76. According to the industry distribution chart, GSK ranks #46 out of 923 companies in the Drug Manufacturers industry, placing it in the top 5%.
Is GSK's Days Payable too high?
GSK's current Days Payable of 435.05 is 204% above median its 10-year median of 143.21. Over the past 10 years, this metric has ranged from a low of 119.83 to a high of 517.76. The Drug Manufacturers industry median Days Payable is 90.98. GSK's value of 435.05 is 378.2% above this industry median. Based on the distribution chart, GSK ranks #46 out of 923 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, GSK has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does GSK's Days Payable compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, GSK ranks #46 out of 923 companies for Days Payable. This places GSK in the top 5% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.98. GSK's value of 435.05 is 378.2% above this benchmark. Historically, GSK's own Days Payable has ranged from 119.83 to 517.76 over the past decade. While the company's 10-year median is 143.21 vs. the industry median of 90.98, GSK has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.98, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GSK's current Days Payable of 435.05 is 378.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on GSK and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GSK's current Days Payable is 435.05, which is 204% above median its own 10-year median of 143.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (MEX:GSKN) is currently considered Fairly Valued. The stock's GF Value™ is MXN818.82, compared to a current price of MXN901.11 — trading 10% above its estimated fair value. The current Days Payable is 435.05, which is 204% above median its 10-year median of 143.21 and 378.2% above the Drug Manufacturers industry median of 90.98. GSK's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For GSK (MEX:GSKN), the current Days Payable is 435.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GSK (MEX:GSKN) Overvalued in 2026?
Based on GuruFocus' analysis, GSK stock appears to be overvalued.
The current stock price of MXN901.11 is trading 10% above its estimated GF Value™ of MXN818.82.
GuruFocus considers GSK to be Fairly Valued.
Key valuation signals for MEX:GSKN:
Days Payable: 435.05 (204% above median its 10-year median of 143.21)
GF Value™: MXN818.82 vs. price of MXN901.11 (10% above fair value)
Industry Position: 378.2% above the Drug Manufacturers median (#46 of 923)
No single metric tells the full story. See the MEX:GSKN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
73GF Score
Get the complete analysis for MEX:GSKN
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:GSKN has been successfully added to your 
